MedTrace Logo

Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis

NCT06885619 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2026-05-12

No results posted yet for this study

Summary

To identify plasma multi-omics biomarkers that predict left ventricular adverse remodeling (LVAR) and major adverse cardiovascular events (MACE) in patients with acute ST-segment elevation myocardial infarction, and to investigate the molecular pathways linked to LVAR and MACE.

Conditions

Interventions

OTHER

Diagnostic Test: echocardiography and blood collection

Blood samples were collected from all patients at enrollment (within 24 hours after primary PCI), at days 3-5, and at months 1, 3, and 6 after enrollment. Echocardiography was performed at enrollment (baseline, within 24-48 hours after admission), and at months 1, 3, and 6 after enrollment.

Sponsors & Collaborators

  • Beijing Jishuitan Hospital

    collaborator OTHER

  • Institute of Biophysics, Chinese Academy of Sciences

    collaborator UNKNOWN

  • Beijing Anzhen Hospital

    lead OTHER

Principal Investigators

  • Xu Wang, Dr. · Beijing Anzhen hospital, Capital Mediacl University.

  • Tanxi Cai, Dr. · Institute of Biophysics, Chinese Academy of Sciences

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-01
Primary Completion
2027-12-31
Completion
2027-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06885619 on ClinicalTrials.gov